Knowledge & Resources
Expert insights and knowledge on global Innovative Contracting, VBA,
Market Access and Human Performance Factors
Innovative Contracting & VBA
Articles & Whitepapers
Analysis showing orphan drug list prices significantly higher in the U.S. than in the E.U. prompts questions about future pricing considerations for gene therapies
An analysis of orphan drug prices in the US raises concerns over the sustainability of gene therapy costs. This article explores factors influencing US drug prices , the potential impact of new EU pharmaceutical legislation and how pressure to curb spiralling drug prices is falling on US policy makers.
An Update on Novartis’ Ambitious Leqvio Strategy in the US
An update on Novartis’ ambitious Leqvio strategy in the U.S.: On Tuesday, in the investor call to announce their interim (Q3) results, the company gave an update on the product’s roll-out.
Indication-Based Pricing: The Simplest Explanation You’ll Ever Read
We examine the complexities of pricing pharmaceuticals with multiple uses or "indications". In contrast with uniform pricing, 'indication-based pricing' (IBP) aligns price with value for each use. We explore successful IBP strategies, challenges like legislative barriers and complex data collection, and discover how IBP benefits both healthcare systems and patients.
A payer’s perspective: Is the contracting landscape for Cell and Gene Therapies unsustainable?
In recent years, the cell and gene therapy market has been touted as a promising frontier in the pharmaceutical industry. Numerous clinical trials and regulatory approvals have driven a wave of investment and innovation. However, some analyst commentary is starting to question whether the market's early momentum has begun to wane. Despite a pipeline of nearly 400 ongoing clinical trials in Europe alone, doubts remain about whether these products will make it to market and if the recent flurry of activity is sustainable.
Analysis: Lessons from Novartis’ Approach to Population Health Management & Innovative Financing Models
Novartis, leader in the Population Health Management approach to expanding patient access to medicines, initiated a program in collaboration with NHS England to reduce low-density lipoprotein levels in patients with atherosclerotic cardiovascular disease, targeting up to 300,000 patients over three years. While the approach has seen success, challenges persist in its implementation, including technical, mindset, and regulatory barriers.
Announcements from South Korea (SK) to Denmark (DK) pave the way for further outcomes-based contracting for high-cost oncology drugs
Multi-indication and combination therapies are rapidly influencing the oncology marketplace. Faced with increasing treatment complexity and budget demands, payers across the globe are starting to evolve their approach to contracting.
Navigating the Maze: A Guide to Evaluating Innovative Contracts in the Pharma Industry
While there’s ample discussion around the theory of innovative contracting and various case studies illustrating its successful implementation globally, accurately measuring the impact of these agreements remains a relatively uncharted territory…
Is VBP the new VBC for U.S. Drug Prices?
All U.S. healthcare stakeholders recognize that the overheated drugs market is not sustainable. The ever-growing spiral of rising gross prices, often accompanied by increasing rebates and returns, is not a model fit for purpose now, let alone the future.
Value-based Agreements deliver U.S. Patient and Caregiver Benefits: New Evidence
National and regional payers identify the real-world advantages of innovative contracts